Table 1.
Baseline Characteristics of the Entire Cohort
| Variable | Frequency | Percentage |
|---|---|---|
| Age (y) | ||
| Mean | 66.4 | |
| Median | 68.2 | |
| Male sex | 28 | 90.3 |
| Etiology of HCC | ||
| Hepatitis B virus | 4 | 12.9 |
| Hepatitis C virus | 17 | 58.8 |
| EtOH | 7 | 22.6 |
| NAFLD | 4 | 12.9 |
| MELD | ||
| Mean | 10 | |
| Median | 10 | |
| Child-Pugh class | ||
| A | 24 | 77.4 |
| B | 6 | 19.4 |
| ALBI | ||
| Mean score | −2.65 | |
| Grade | ||
| 1 | 17 | 54.8 |
| 2 | 13 | 41.9 |
| ECOG PS | ||
| 0 | 24 | 77.4 |
| 1 | 6 | 19.4 |
| 2 | 0 | 0.0 |
| 3 | 0 | 0.0 |
| 4 | 0 | 0.0 |
| Radioembolization type by tumor | ||
| Segmental | 19 | 58 |
| Nonsegmental | 14 | 42 |
| Tumor distribution | ||
| Solitary | 27 | 90 |
| Multifocal | 3 | 10 |
| Scout90Y activity (GBq) | ||
| Mean | 0.56 | |
| Median | 0.56 | |
| 90Y therapeutic activity (GBq) | ||
| Mean | 1.17 | |
| Median | 0.78 | |
| BCLC Stage | ||
| A | 16 | 53.3 |
| B | 9 | 30.0 |
| C | 5 | 16.7 |
ALBI = albumin-bilirubin; BCLC = Barcelona Clinic Liver Cancer; ECOG PS = Eastern Cooperative Oncology Group performance status; EtOH = ethanol; HCC = hepatocellular carcinoma; MELD = model for end-stage liver disease; NAFLD = non-alcoholic fatty liver disease.